Who
Jodie Pope Morrison
CEO
Company insider
Files Form 4 as: CEO, Q32 Bio; Director, Verve Therapeutics; Director, Rein Therapeutics; Director, Akebia Therapeutics; Interim CEO, Keryx Biopharmaceuticals; President and CEO, Eledon Pharmaceuticals.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $931K
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 22 Sep 2014
- Last trade
- 6 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 14 Oct 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $27K3,221 at $8.32 | filing |
| 25 Aug 2026filed 27 Aug 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $163K9,845 at $16.56 | filing |
| 25 Aug 2026filed 27 Aug 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $163K9,845 at $16.56 | filing |
| 16 Jul 2026filed 20 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —132,000 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —132,000 at $0.00 | filing |
| 25 Feb 2026filed 27 Feb 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $45K9,896 at $4.51 | filing |
| 25 Feb 2026filed 27 Feb 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $45K9,896 at $4.51 | filing |
| 24 Feb 2026filed 20 Mar 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —132,000 at $0.00 | filing |
| 24 Feb 2026filed 20 Mar 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code A | —132,000 at $0.00 | filing |
| 2 Dec 2025filed 4 Dec 2025 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $78K22,506 at $3.46 | filing |
| 26 Aug 2025filed 28 Aug 2025 | QTTB Q32 BioBiotechnology | SEC FORM 4 Sold | $19K10,494 at $1.80 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —267,541 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,200 | filing |
| 5 Jun 2025filed 6 Jun 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code A | —42,200 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —152,700 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —152,700 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —152,700 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —152,700 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —16,901 at $0.00 | filing |
| 24 Feb 2025filed 26 Feb 2025 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —16,901 at $0.00 | filing |
News
Head to Head Review: Q32 Bio (NASDAQ:QTTB) vs. Applied Therapeutics (NASDAQ:APLT)QTTB · tickerreport.com · 15 Oct 2026Head to Head Review: Kyntra Bio (NASDAQ:KYNB) and Q32 Bio (NASDAQ:QTTB)QTTB · tickerreport.com · 12 Oct 2026Contrasting Q32 Bio (NASDAQ:QTTB) and Kyntra Bio (NASDAQ:KYNB)QTTB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Jodie Pope Morrison; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.